News|Videos|November 6, 2023
Practical Guidance for Prostate Cancer Imaging: PSMA-PET Scans and Patient Selection
Author(s)David Albala, MD
David Albala, MD, shares closing advice on using PSMA-PET scans in prostate cancer management and making informed patient selection decisions based on guidelines and practical insights.
Advertisement
Episodes in this series
Advertisement
Related to this article
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
A national study found that use of MRI before prostate biopsy increased in US hospitals from 2017 through the first half of 2026.
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
Advertisement
Advertisement
Trending on Urology Times
1
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
2
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
3
One year of Inlexzo: Evolving care in BCG-unresponsive NMIBC
4
PSMA PET Radiotracers and Access Barriers in Prostate Cancer
5